Clinical Efficacy Of Icotinib Hydrochloride With Advanced Non-small Cell Lung Cancer

Objective:This study was performed to assess the efficacy and toxicity of icotinib hydrochloride as first-line therapy for patients with advanced non-small cell lung cancer with EGFR sensitive mutation.Method:Thirty-seven patients with advanced non-small cell lung cancer with EGFR-sensitive mutation who were sequentially admitted to****** from December 12012 to June 1 2017 were enrolled into our retrospective research.Patients were treated with Icotinib orally three times a day,125 mg each time,until disease progression or intolerance with toxicities.Results:1.Among the 41 patients,four were lost to follow-up,0 case achieved clinical complete response,20 cases achieved partial response,8 cases achieved clinical stable response,5 cases achieved clinical progressive response,the tumor objective response rate and disease control rate were 64.9%(24/37)and 86.5%(32/37),respectively.2.The objective efficiency of exon 19 deletion was significantly higher than that of exon21 L858 R,P<0.05.There was no significant difference in the disease control rate.3.The median progression-free survival was 9.4 months(95% confidence interval [CI]: 7.61�11.19 months),and median overall survival was 27.8 months(95%CI: 22.20�33.40 months).The most common drug-related toxicities were rashesand diarrhea,but these were generally manageable and reversible.4.The serum levels of CEA,CA125 and CYFRA21-1 in 37 patients were significantly decreased with statistical significance.The serum levels of 5 progressive patients were elevated.5.Age,sex,gene mutations and patnological stage had no significant effect on mPFS and mOS.Smoking affected the patient's survival time,The ECOG score affected the median progression-free survival in patients.Conclusion: The icotinib hydrochloride is effective and safe in treating the treatment-experienced patients with advanced non-small cell lung cancer,especially for patients with sensitive mutations.